ArticleAmerican journal of translational research2022
Correlation of serum NLR, PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Prognostic value of the HALP score in breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Pooled it
- Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Article
- Development and internal validation of a nomogram for predicting neoadjuvant therapy efficacy in breast cancer based on the HALP score.Translational cancer research · 2026Article
- PIV, PNI and HALP score for predicting pathological complete response in breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Article
- CALLY index as an independent predictor of pathological complete response in HER2-positive breast cancer receiving neoadjuvant therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Clinical significance of peripheral blood parameters as a prognostic biomarker in patients receiving neoadjuvant chemotherapy for breast cancer.BMC cancer · 2026Article
- The preoperative hemoglobin, albumin, lymphocyte, and platelet score as a prognostic Indicator for survival in gastric and colorectal cancer patients.Frontiers in nutrition · 2026Article
- Machine learning and SHAP value interpretation for predicting the response to neoadjuvant chemotherapy and long-term clinical outcomes in Chinese female breast cancer.Annals of medicine · 2025Article
- The Role of Systemic Inflammatory Indices in Predicting Composite Adverse Outcomes of Peripartum Hemorrhage Treated with Fibrinogen Concentrate.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- A Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value.Journal of clinical medicine · 2025Article
- Article
- Single-cell transcriptomic profiling of immune landscape in triple-negative breast cancer during neoadjuvant chemotherapy.NPJ systems biology and applications · 2025Article
- Unveiling the Diagnostic Potential of Platelet-to-Lymphocyte Ratio and HALP Score in Newly Diagnosed Breast Cancer: A Step Toward Early Detection.European journal of breast health · 2025Article
- Circulating chemokines and leukocytes and their impact on breast cancer prognosis.Discover oncology · 2025Article
- Inflammation-related biomarkers as predictors of pathological complete response in early-stage breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Can pretreatment lactate dehydrogenase to albumin ratio predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients?Journal of medical biochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the correlation of blood neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) with the efficacy of neoadjuvant chemotherapy (NAC) and the prognosis of triple-negative breast cancer (TNBC).
methodsIn this retrospective study, clinical data of 92 patients with TNBC were analyzed. The patients were treated with NAC in the Department of Gynecology of the People's Hospital of Zhuji from January 2015 to December 2018. According to treatment efficacy of NAC, patients were divided into a pathologic complete response (pCR) group (n=37) and a non-pathologic complete response (non-pCR) group (n=55). The pathological and clinical data of patients were collected, and the efficacy of NAC and influencing factors were statistically analyzed. The predicting performances of NLR, PLR and HALP for the efficacy of NAC in patients with TNBC were investigated. Patients were followed up for 3 years to obtain the all-cause mortality so as to analyze the correlation of NLR, PLR and HALP with survival time.
resultsMultivariate regression analysis showed that TNM stage III (OR (95% CI): 1.742 (1.209-2.631), P=0.003), lymph nodes metastasis (OR (95% CI): 1.922 (1.492-2.983), P =0.005), high NLR (OR (95% CI): 2.261 (1.625-2.754), P<0.001), high PLR (OR (95% CI): 2.062 (1.692-2.791), P<0.001) and low HALP (OR (95% CI): 0.518 (0.365-0.734), P<0.001) were risk factors of poor NAC efficacy for TNBC. The mortality of patients in the non-pCR group was higher than that in the pCR group within 3 years (P<0.05). Survival analysis showed that the 3-year survival rate of the non-pCR group was lower than that of the pCR group (P<0.05). Furthermore, patients with high NLR, high PLR and low HALP had a lower 3-year survival rate than those with low NLR, low PLR and high HALP (P<0.05).
conclusionsLymph node metastasis, TNM stage III, high NLR, high PLR and low HALP are risk factors for the poor efficacy of NAC for TNBC. High expression of NLR, PLR and low expression of HALP may indicate a poor prognosis of TNBC patients who failed NAC.
Indexed as
Identifiers
35702128PMC9185079W4285744701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.